StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
October 1, 2026 3:10 PM
Baird analyst Brian Skorney reiterated a Neutral rating and $761.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments "Positive ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
